July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Effects of a novel glaucoma eye drop Mikeruna®
Author Affiliations & Notes
  • Rika Yamada
    ophthalmology, Niimi Eye Institute, Saitama, Saitama, Japan
  • KOJI NIIMI
    ophthalmology, Niimi Eye Institute, Saitama, Saitama, Japan
  • Footnotes
    Commercial Relationships   Rika Yamada, None; KOJI NIIMI, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2396. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rika Yamada, KOJI NIIMI; Effects of a novel glaucoma eye drop Mikeruna®. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2396.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We evaluated the effects of Mikeruna®, a combined glaucoma eye drop solution containing latanoprost and carteolol.

Methods : We studied 152 eyes of 95 patients with primary open angle glaucoma, primary angle closure glaucoma, and normal tension glaucoma. These patients had initially used a combination of prostaglandin and β blocker drugs such as Xalacom®, Duo Trav®, and Tapcom®; for the study, patients changed to Mikeruna®, a compound drug comprising a prostaglandin (latanoprost) and carteolol. We evaluated the lowering effect and complications of Mikeruna® and compared the results with those of other drug combinations. Intraocular pressure (IOP) was measured monthly, and the average value of three measurements before and after switching to Mikeruna® was adopted. To eliminate differences among examiners, all measurements were taken with the same intraocular pressure-measuring instrument.

Results : In the case of change of Xalacom® (Latanoprost Timolol maleate, Pfizer Inc., NY, U.S.A) to Mikeruna®, intraocular pressure decreased from 11.77 mmHg to 11.18 mmHg (n=90). The change from Duo Trav® (Travoprost Timolol maleate, Alcon Inc., Hünenberg, Swiss) to Mikeruna® lowered IOP from 14.62 mmHg to 14.10 mmHg (n=56). The switch from Tapcom® (Tafluprost Timolol maleate, Santen Pharmaceutical Co., Ltd., Tokyo, Japan) to Mikeruna® lowered IOP from 14.47 mmHg to 13.37 mmHg (n=6). Use of Mikeruna® did not result in obvious complications.

Conclusions : here was no significant difference in ocular lowering effect on changing glaucoma medication to Mikeruna®. Nevertheless, there were no increases in complications, and patients experienced easier instillation and eye drop comfort.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×